Why the study?
Although novel cryoballoon ablation systems like PolarX are widely used, clear advantages over previous cryoballoon technologies have not been demonstrated.
Does the PolarX cryoballoon ablation system reduce atrial fibrillation or atrial tachycardia recurrence compared to the Arctic Front system in patients with paroxysmal or persistent atrial fibrillation?
Does the PolarX cryoballoon ablation system reduce atrial fibrillation or atrial tachycardia recurrence compared to the Arctic Front system in patients with paroxysmal or persistent atrial fibrillation?
The PolarX cryoballoon system may provide superior procedural outcomes compared to the Arctic Front system specifically in patients with persistent atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for PolarX benefit in persistent AF; randomized trials needed before practice change.
Although novel cryoballoon ablation systems like PolarX are widely used, clear advantages over previous cryoballoon technologies have not been demonstrated.In this study, PolarX showed no significant difference in atrial fibrillation (AF)/atrial tachycardia recurrence compared to the Arctic Front cryoballoon system in patients with paroxysmal AF (hazard ratio [HR], 1.23; 95% confidence interval [CI], 0.63-2.42;P = 0.546), but significantly reduced recurrence in those with persistent AF (HR, 0.45; 95% CI, 0.24-0.99;P = 0.022).These findings suggest that, in patients with persistent AF, selecting a specific cryoballoon system like PolarX may lead to better procedural outcomes.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: